Xenetic Biosciences (XBIO) Retained Earnings (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Retained Earnings came in at -$200.3 million in Q1 2026, down 196.2% YoY from $208.2 million in Q1 2025, and down 194.36% on a QoQ basis from $212.3 million in Q4 2025.
Xenetic Biosciences (XBIO) Retained Earnings (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Retained Earnings data on file, last reported at -$200.3 million in Q1 2026.
- Quarterly Retained Earnings fell 196.2% year-over-year to -$200.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$200.3 million (down 196.2% YoY) and the FY2025 annual result came in at $212.3 million, up 1.95% from the prior year.
- Retained Earnings slipped to -$200.3 million in Q1 2026, from $212.3 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $212.3 million in Q4 2025 to a low of -$200.3 million in Q1 2026.
- A 5-year average of -$6.3 million and a median of $253734.0 in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings sank 75378.49% — and 2024, when it soared 208.99%.
- Tracing XBIO's Retained Earnings over 5 years: stood at $207.8 million in 2022, then tumbled by 193.0% to -$193.2 million in 2023, then soared by 207.76% to $208.2 million in 2024, then increased by 1.95% to $212.3 million in 2025, then plunged by 194.36% to -$200.3 million in 2026.
- The last three Retained Earnings figures came in at -$200.3 million (Q1 2026), $212.3 million (Q4 2025), and $253734.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | 212.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 212.36 Mn |
| Mar 31, 2026 | -200.33 Mn |
| Dec 31, 2025 | 212.29 Mn |
| Sep 30, 2025 | 253,734.00 |
| Jun 30, 2025 | -198.79 Mn |
| Mar 31, 2025 | 208.24 Mn |
| Dec 31, 2024 | 208.23 Mn |
| Sep 30, 2024 | 253,734.00 |
| Jun 30, 2024 | 208.17 Mn |
| Mar 31, 2024 | -194.43 Mn |
| Dec 31, 2023 | -193.23 Mn |
| Sep 30, 2023 | -192.06 Mn |
| Jun 30, 2023 | -191.01 Mn |
| Mar 31, 2023 | -189.96 Mn |
| Dec 31, 2022 | 207.77 Mn |
| Sep 30, 2022 | 207.15 Mn |
| Jun 30, 2022 | 253,734.00 |
| Mar 31, 2022 | 253,734.00 |
| Dec 31, 2021 | 205.95 Mn |
| Sep 30, 2021 | 205.88 Mn |